Examples of using Dose modifications in English and their translations into Polish
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Financial
-
Official/political
-
Programming
-
Computer
Dose modifications for toxicity when Xeloda is used as a 3 weekly cycle in combination with other agents.
Further dose modifications should be based on the safety
Dose modifications for toxicity when Xeloda is used continuously in combination with other agents.
These differences do not affect exposure due to weight-based dosing and no dose modifications based on gender are required.
Recommended dose modifications for toxicities in patients treated with docetaxel in combination with cisplatin and 5-fluorouracil 5-FU.
Dose modifications(interruptions or reductions)
Dose modifications applied should be applied for the precipitating adverse event as necessary see section 4.2.
For recommended dose modifications and measures in case of hand-foot skin reaction(HFSR)/ palmar-plantar erythrodysesthesia syndrome see Table 1.
Dose modifications for toxicity when capecitabine is used as a 3 weekly cycle in combination with other medicinal products.
Dose modifications for Teysuno for adverse reactions in general except for haematologic and renal toxicities.
For recommended measures and dose modifications in case of worsening of liver function tests considered related to treatment with Stivarga see Table 2 see also section 4.4.
There are no dose modifications recommended for severe lymphopenia given the mechanism of action of MabCampath.
Insufficient data are currently available to recommend dose modifications in patients with mild to moderate hepatic impairment see sections 4.4. and 5.2.
For docetaxel and other chemotherapy dose modifications, see relevant summary of product characteristics SmPC.
Table 2: Dose modifications for neutropenia and/or thrombocytopenia at the start of a cycle
Dose modifications or interruption of dosing should be considered for the management of haematological and non-haematological toxicities.
Dose modifications for toxicity should be made according to Tables 1, 3, 4, and 5.
For recommended dose modifications based on ANC and platelet counts,
Dose modifications for neutropenia(ANC*< 1.0 x 109/L) and thrombocytopenia(platelet<
insufficient data are currently available to recommend dose modifications in patients with renal impairment see section 5.2.